Contribution of non-traditional lipid profiles to reduced glomerular filtration rate in H-type hypertension population of rural China

References

• Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223.
   PubMed Web of Science ®Google Scholar
• Lewington S, Lacey B, Clarke R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med. 2016;176:524–532.
   PubMed Web of Science ®Google Scholar
• Ye Z, Wang C, Zhang Q, et al. Prevalence of homocysteine-related hypertension in patients with chronic kidney disease. J Clin Hypertens. 2017;19: 151–160.
   Web of Science ®Google Scholar
• Chen Z, Wang F, Zheng Y, et al. H-type hypertension is an important risk factor of carotid atherosclerotic plaques. Clin Exp Hypertension (New York, NY: 1993). 2016;38:424–428.
   PubMed Web of Science ®Google Scholar
• Qin X, Huo Y. H-Type hypertension, stroke and diabetes in China: Opportunities for primary prevention. J Diabetes. 2016;8:38–40.
   PubMed Web of Science ®Google Scholar
• Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313:1325–1335.
   PubMed Web of Science ®Google Scholar
• Towfighi A, Markovic D, Ovbiagele B. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study. J Neurol Sci. 2010;298:153–157.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fang X, Hua Y, et al. Combined effect of hyperhomocysteinemia and hypertension on the presence of early carotid artery atherosclerosis. J Stroke Cerebrovasc Dis. 2016;25:1254–1262.
   PubMed Web of Science ®Google Scholar
• Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal substudy of the China stroke primary prevention trial. JAMA Intern Med. 2016;176:1443–1450.
   PubMed Web of Science ®Google Scholar
• Xie D, Yuan Y, Guo J, et al. Hyperhomocysteinemia predicts renal function decline: a prospective study in hypertensive adults. Sci Rep. 2015;5:16268.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262–F272.
   PubMed Web of Science ®Google Scholar
• Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008;28:723–731.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31:189–196.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O'Donnell MP, Schmitz PG, et al. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int. 1990;37:880–891.
   PubMed Web of Science ®Google Scholar
• Ganda A, Magnusson M, Yvan-Charvet L, et al. Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation. 2013;127:988–996.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6:287–296.
   PubMed Web of Science ®Google Scholar
• Bowe B, Xie Y, Xian H, et al. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016;89:886–896.
   PubMed Web of Science ®Google Scholar
• Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091.
   PubMed Web of Science ®Google Scholar
• Rahman M, Yang W, Akkina S, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol: CJASN. 2014;9:1190–1198.
   PubMed Web of Science ®Google Scholar
• Chawla V, Greene T, Beck GJ, et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol. CJASN. 2010;5:1582–1587.
   PubMed Web of Science ®Google Scholar
• Barzi F, Patel A, Woodward M, et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol. 2005;15:405–413.
   PubMed Web of Science ®Google Scholar
• Bittner V, Johnson BD, Zineh I, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J. 2009;157:548–555.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55:35–41.
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–333.
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776–785.
   PubMed Web of Science ®Google Scholar
• Elshazly MB, Quispe R, Michos ED, et al. Patient-level discordance in population percentiles of the total cholesterol to high-density lipoprotein cholesterol ratio in comparison with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol: the very large database of lipids study (VLDL-2B). Circulation. 2015;132:667–676.
   PubMed Web of Science ®Google Scholar
• Mathews SC, Mallidi J, Kulkarni K, et al. Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data. PLoS One. 2012;7:e33692.
   PubMed Web of Science ®Google Scholar
• Salazar MR, Carbajal HA, Espeche WG, et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol. 2012;109:1749–1753.
   PubMed Web of Science ®Google Scholar
• Bhalodkar NC, Blum S, Enas EA. Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians. Am J Cardiol. 2006;97:1007–1009.
   PubMed Web of Science ®Google Scholar
• Katakami N, Kaneto H, Osonoi T, et al. Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients. Atherosclerosis. 2011;214:442–447.
   PubMed Web of Science ®Google Scholar
• Tsuruya K, Yoshida H, Nagata M, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. 2014;233:260–267.
   PubMed Web of Science ®Google Scholar
• Tsuruya K, Yoshida H, Nagata M, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–983.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yuan Z, Chen W, et al. Serum lipid profiles, lipid ratios and chronic kidney disease in a Chinese population. IJERPH. 2014;11:7622–7635.
   Google Scholar
• Kim JY, Kang HT, Lee HR, et al. Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in Korean adults. J Korean Med Sci. 2012;27:1524–1529.
   PubMed Web of Science ®Google Scholar
• Li Z, Bai Y, Guo X, et al. Alcohol consumption and cardiovascular diseases in rural China. Int J Cardiol. 2016;215:257–262.
   PubMed Web of Science ®Google Scholar
• Sun GZ, Guo L, Wang XZ, et al. Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study. Int J Cardiol. 2015;182:13–17.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Astor BC, Kramer H, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008;3:125–132.
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016.
   PubMed Web of Science ®Google Scholar
• Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412–424.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192.
   PubMed Web of Science ®Google Scholar
• Kang HT, Shim JY, Lee YJ, et al. Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean National Health and Nutrition Examination Survey. Kidney & Kidney Blood Press Res. 2011;34:173–179.
   PubMed Web of Science ®Google Scholar
• Cerasola G, Mule G, Nardi E, et al. Clinical correlates of renal dysfunction in hypertensive patients without cardiovascular complications: the REDHY study. J Hum Hypertens. 2010;24:44–50.
   PubMed Web of Science ®Google Scholar
• Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dialy Transplant. 1999;14:1462–1466.
   PubMed Web of Science ®Google Scholar
• Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503–516.
   PubMed Web of Science ®Google Scholar
• Dogra G, Irish A, Chan D, et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006;48:926–934.
   PubMed Web of Science ®Google Scholar